NOTV News & Events

Inotiv announced a strategic initiative to leverage LifeNet Health's proprietary TruVivo within its Discovery and Translational Sciences business. LifeNet Health has developed the patented TruVivo system, which uses primary human hepatocytes cultured with human-derived feeder cells to create physiologically relevant in vitro models. This technology provides a stronger foundation for predicting human responses to new therapies and addresses a critical challenge in drug development.

Inotiv and Vugene, a multi-omics data analysis company providing advanced artificial intelligence and machine learning solutions for biomedical research, announced a strategic collaboration designed to accelerate AI-assisted drug discovery and enhance data-driven insights across the drug development continuum. Inotiv will integrate Vugene's cloud-based bioinformatics and computational platform into its Discovery & Translational Sciences Division.

Book-to-bill ratio for FY25 is anticipated to be approximately 1.05x for the DSA services business.